Acadia Pharmaceuticals Inc. (ACAD) is a publicly traded Healthcare sector company. As of May 21, 2026, ACAD trades at $20.95 with a market cap of $3.54B and a P/E ratio of 9.34. ACAD moved +2.25% today. Year to date, ACAD is -19.89%; over the trailing twelve months it is -3.41%. Its 52-week range spans $13.40 to $28.35. Analyst consensus is strong buy with an average price target of $32.77. Rallies surfaces ACAD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for ACAD combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $20.95 |
| Market Cap | $3.54B |
| P/E Ratio | 9.34 |
| EPS | $2.23 |
| Dividend Yield | 0.00% |
| 52-Week High | $28.35 |
| 52-Week Low | $13.40 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $1.10B |
| Net Income | $375.65M |
| Gross Margin | 91.47% |
15 analysts cover ACAD: 0 strong buy, 12 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $32.77.